Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by SPCEO1on Aug 01, 2022 10:23am
126 Views
Post# 34863959

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Comparing Corporate Presentations

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Comparing Corporate PresentationsYou may have noticed the week has just begun - maybe your assessment for the whole week is a bit premature??? 

That being said, those 230,000 $0.38 options that are expiring on12/20/22 for Lafond and Marsolais are going to be exercised at some point between now and then, or perhaps at many points. While it was discouraging to see Lafond sell his, I am most interested in seeing how Marsolais handles his. 

As for the run in those other stocks, while THTX gets left behind yet again, it certainly is peculiar as TH's situation is and always has been clearly better than that of CYDY, for example. Way, eay better since CYDY is something of a criminal enterprise. But CYDY pursued a retail investor strategy and TH did not. Retail investors are not aware of TH's merits and institutional shareholders are largely unable to purchase it. Thus the lack of interest even while TH is an undeniably superior company with the possibility of being on a track similar to IMMU that legitimately gives it a chance at massive upside. The situation can be fixed but my sense is TH still remains fixated on institutional investors who may be intrigued by the story TH can tell about massive potential cancer upside but cannot buy the stock due to its low price and tiny market cap. When was the last time TH spoke publically to any investors at a conference? Maybe TH knows it is on the cusp of a big development in cancer and is holding its cards close to its vest until it can announce whatever that may be. The new IR officer apparently has big plans to put TH in front of a lot of investors over the next year but if those investors are mostly institutional and the stock price and market cap are where they are now, it is going to be hard for those meetings to pay off. 

Biobob wrote: Another week of nothing coming up again... maybe some option action from our big beleivers overthere... Cytodyn doubled in past month.. Bellus is worth 5 times more... nothing very exciting with those... Cytodyn has like 20 lwasuits... Bellus has been able to raise cash for their cought drug... yep cough... that's a killer... cough... lol


<< Previous
Bullboard Posts
Next >>